Adjunctive aripiprazole for bupropion-resistant major depression.

about

Emerging targets for antidepressant therapies Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.

P2860

Q28247614-FA48AD70-ADCA-4A6B-BB99-BC48459DBCDC Q30411445-AC2833BD-AD8B-47F5-A988-E698AA1CCACE

P2860

Adjunctive aripiprazole for bupropion-resistant major depression.

Item

http://www.wikidata.org/entity/Q45229981

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Adjunctive aripiprazole for bupropion-resistant major depression.

@en

Adjunctive aripiprazole for bupropion-resistant major depression.

@nl

type

Item

label

Adjunctive aripiprazole for bupropion-resistant major depression.

@en

Adjunctive aripiprazole for bupropion-resistant major depression.

@nl

prefLabel

Adjunctive aripiprazole for bupropion-resistant major depression.

@en

Adjunctive aripiprazole for bupropion-resistant major depression.

@nl

P1476

Adjunctive aripiprazole for bupropion-resistant major depression.

@en

P2093

Kenneth N Sokolski

http://www.w3.org/2001/XMLSchema#string

P2860

The role of dopamine in the pathophysiology of depression

A new depression scale designed to be sensitive to change

A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.

Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability.

Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation.

Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.

Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies.

An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression

Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study.

Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients.

P304

1124-1129

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1K630

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18492784

http://www.w3.org/2001/XMLSchema#string

Adjunctive aripiprazole for bupropion-resistant major depression.

about

P2860

P2860

Adjunctive aripiprazole for bupropion-resistant major depression.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698